Evidence map›Paper›PMID 27983523›Full record

ArticleCancer biomarkers : section A of Disease markers2017

CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.

Saoussen Debouki-Joudi, Fatma Trifa, Abdelmajid Khabir, Tahia Sellami-Boudawara, Mounir Frikha, Jamel Daoud, Raja Mokdad-Gargouri

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. APC Promoter Hypermethylation as a Prognostic Marker in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2020
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Saoussen Debouki-JoudiLaboratory of Molecular Biotechnology of Eukaryotes, Department of Cancer Genetics, Center of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.
Fatma TrifaLaboratory of Molecular Biotechnology of Eukaryotes, Department of Cancer Genetics, Center of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.
Abdelmajid KhabirCentre Hospitalo-Universitaire Habib Bourguiba, Sfax 3000, Tunisia.
Tahia Sellami-BoudawaraCentre Hospitalo-Universitaire Habib Bourguiba, Sfax 3000, Tunisia.
Mounir FrikhaCentre Hospitalo-Universitaire Habib Bourguiba, Sfax 3000, Tunisia.
Jamel DaoudCentre Hospitalo-Universitaire Habib Bourguiba, Sfax 3000, Tunisia.
Raja Mokdad-GargouriLaboratory of Molecular Biotechnology of Eukaryotes, Department of Cancer Genetics, Center of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia.
Hopital Universitaire Habib Bourguiba · TNCentre of Biotechnology of Sfax · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour suppressor gene (TSG) silencing through promoter hypermethylation plays an important role in cancer initiation. The aim of this study was to assess the extent of methylation of APC gene promoter in 91 sporadic and 44 familial cases of Tunisian patients with breast cancer (BC) in. The frequency of APC promoter methylation is somewhat similar for sporadic and familial breast cancer cases, (52.1%, and 54.5% respectively). For sporadic breast cancer patients, there was a significant correlation of APC promoter hypermethylation with TNM stage (p = 0.024) and 3-year survival (p = 0.025). Regarding the hormonal status (HR), we found significant association between negativity to PR and unmethylated APC (p= 0.005) while ER and Her2/neu are not correlated. Moreover, unmethylated APC promoter is more frequent in tumours expressing at least one out the 3 proteins compared to triple negative cases (p= 0.053). On the other hand, aberrant methylation of APC was associated with tumour size (p = 0.036), lymph node (p = 0.028), distant metastasis (p = 0.031), and 3-year survival (p = 0.046) in the group of patients with familial breast cancer. Moreover, patients with sporadic breast cancer displaying the unmethylated profile have a significant prolonged overall survival compared to those with the methylated pattern of APC promoter (p log rank = 0.008). Epigenetic change at the CpG islands in the APC promoter was associated with the silence of its transcript and the loss of protein expression suggesting that this event is the main mechanism regulating the APC expression in breast cancer. In conclusion, our data showed that the loss of APC through aberrant methylation is associated with the aggressive behavior of both sporadic and familial breast cancer in Tunisian patients.

Indexed as

CpG IslandsPromoter Regions, GeneticAdenomatous Polyposis Coli ProteinAdultAgedAged, 80 and overBreast NeoplasmsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedTunisiaAdenomatous Polyposis Coli ProteinAPC protein, humanAPCBreast cancerCpG methylationepigenetictranscriptional silencing

Identifiers

PMID27983523
PMCPMC13020579
OpenAlexW2561395688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.